Back to Search
PATRICK RICHARDSON, RPH, PHARMD
RPH, PHARMD
Pharmacist
NPI: 1841702115Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
PHCY-04356(NH)
Research & Publications (20)
The effects of flexible bronchoscopy on mechanical ventilation in a pediatric lung model.
PMID 18812449·Chest·2009
8-other
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
PMID 19471019·Blood·2009
3-trial
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
PMID 18297527·Leuk Lymphoma·2008
3-trial
The emerging role of novel therapies for the treatment of relapsed myeloma.
PMID 17335684·J Natl Compr Canc Netw·2007
6-review
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
PMID 17451408·Br J Haematol·2007
2-rct
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
PMID 16830422·Clin Adv Hematol Oncol·2006
8-other
Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
PMID 16773847·Oncology (Williston Park)·2006
5-case
Can thalidomide improve outcome in patients with multiple myeloma?
PMID 17080171·Nat Clin Pract Oncol·2006
8-other
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
PMID 16832859·Clin Adv Hematol Oncol·2006
8-other
Bortezomib: proteasome inhibition as an effective anticancer therapy.
PMID 16409135·Annu Rev Med·2006
6-review
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PMID 16754936·J Clin Oncol·2006
3-trial
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
PMID 16470606·Cancer·2006
3-trial
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
PMID 16344100·Semin Hematol·2005
6-review
Bortezomib: proteasome inhibition as an effective anticancer therapy.
PMID 16555986·Future Oncol·2005
6-review
Emerging trends in the clinical use of bortezomib in multiple myeloma.
PMID 16231845·Clin Lymphoma Myeloma·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 15 STARRETT DR UNIT G
BELFAST, ME 04915 - Phone
- (207) 474-3393
Quick Facts
- NPI
- 1841702115
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile